| Abstrakt: |
A study conducted by Iran University of Medical Sciences examined the use of immune checkpoint inhibitors (ICIs) in the treatment of gastrointestinal (GI) cancers. The study found that ICIs, particularly programmed death-1 (PD-1) inhibitors like Camrelizumab and Sintilimab, showed promise in improving response rates in patients with GI cancers compared to conventional therapies. However, the efficacy of ICIs varied among different types of GI cancers, with hepatocellular carcinoma (HCC) and esophageal cancer (EC) patients being better candidates for ICI therapy than gastric cancer (GC) and colorectal cancer (CRC) patients. The study also highlighted the importance of further research to optimize the use of ICIs in GI cancers and to better understand their adverse effects. [Extracted from the article] |
